Assessing the Growing Role & the Demand of Apps in Managing the Chronic Diseases

Central Nervous System

How Depression Is Eroding The Mental And The Ph...

Depression is a global health burden and continues to increase with each passing day. As per the WHO, globally, more than 264 million people of all ages suffer from depression. It is one of the lea...

Mar 31, 2021

Latest-biotech-pharma-news-updates-for-ajinomot-pfizer-ikena-lilly-bright-peak
Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer’s Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing

Bright Peak Therapeutics, Ajinomoto Collaborates to Create Novel Immunocytokines Bright Peak Therapeutics has announced a research and licensing collaboration with Ajinomoto to incorporate AJICAP,  Ajinomoto Co.’s proprietary site-specific bioconjugation technology, for the development of Bright Peak Immuno...

Find More
recent-pharma-happenings-for-asher-bio-roche-novartis-epimab
Asher Bio raises $55M; Roche halts Huntington’s phase 3 trial; Novartis’ radioligand hits goal in phase 3; EpimAb raises $120M in Series C

Asher Bio raises USD 55 Million in Series A financing Asher Biotherapeutics, a biotechnology company developing exactly targeted immunotherapies for cancer and other diseases, raised USD 55 Million in Series A financing. Third Rock Ventures led the round with participation from Boxer Capital of Tavistock Grou...

Find More
Drug-resistant Epilepsy Market
Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape?

Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape? In the United States, more than 2.5 million people are living with Epilepsy, out of which approximately 1 million continue to experience seizures despite adequate treatment with antiseizure drugs. Known as Drug-resistant epilep...

Find More

More Views & Analysis

pharma-happenings-for-gbt-sanofi-eli-lilly-glooko-solid-biosciences
GBT strikes a deal with Sanofi; Lilly’s IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy

Global Blood Therapeutics strikes a deal with Sanofi for sickle cell disease programs As Global Blood Therapeutics works to bring its sickle cell disease drug, Oxbryta, to younger patients, the company is reinforcing its pipeline with a pair of early-stage programs from Sanofi. In exchange for the global righ...

Find More

Chronic Pain Market Landscape | Chronic Pain Pipeline | Osteoarthritis
Emerging Therapies in the Chronic Pain Pipeline Transforming the Chronic Pain Market Landscape

More than 100 million people are living with one or the other form of Chronic Pain in the USA, says the Institute of Medicine. The available treatments to tackle cancer, as well as non-cancer pain, include nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, or combinations of opioids and non-narc...

Find More

pharma-happenings-for-valo-health-ventyx-takeda-maverick-therapeutics
Valo Health receives $110M Series B Cognito’s therapy slows Alzheimer’s disease Ventyx Biosciences raises $114M Takeda expands immuno-oncology portfolio

Valo Health receives USD 110 Million Series B from Koch Valo Health launched in September with USD 100 million and a couple of acquisitions under its belt to transform drug development and cut years off R&D timelines. Now, it is filling with USD 110 million from Koch Disruptive Technologies that will bolster...

Find More

Gene and Cell Therapies in CNS Disorders
Gene and Cell Therapies in CNS Disorders: Miracle Cure? Opportunities Galore!

CNS disorders are a wide-ranging set of disorders in which the brain loses its normal functioning, limiting everyday ability to function. These may arise from various reasons-some are inherited, some result from damage, and some from infections. It contributes to the highest disability-adjusted life years. The curr...

Find More

recent-pharma-happenings-for-bluebird-pfizer-guardant-astrazeneca
Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval

Bluebird suspends gene therapy trials after two sickle cell patients develop cancer Bluebird bio has stopped two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). During the pause, bluebird will assess whether the ...

Find More

Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda’s Maribavir; Astellas/Seagen Padcev
Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda’s Maribavir; Astellas/Seagen Padcev

Merck's Keytruda-Eisai's Lenvima Combo Make the Cut in Renal Cancer Numerous immunotherapy-based combinations are already trying in the old game of gleek to stake up some share in previously untreated, metastatic kidney cancer; however, the market seems to expand as the new entrants continue to make their entry....

Find More

Though Covid-19 has a significant impact on the supply chain, input costs, logistics, and raw materi.....

Find More

The coronavirus outbreak has affected thousands of people in at least 186 countries which has also a.....

Find More

Virtual clinical trials (VCTs) are site-less clinical trials, which utilizes technology along with t.....

Find More

A rare glomerular kidney-scarring disease, Focal Segmental Glomerulosclerosis (FSGS) is a disease wi.....

Find More

AAV Vectors are the leading viral vectors for gene delivery to treat a variety of human diseases. Ad.....

Find More

Gastroesophageal Reflux Disease (GERD, also known as chronic acid reflux) is a digestive disorder in.....

Find More